ProShares Ultra NASDAQ Biotechnology
BIB
BIB
40 hedge funds and large institutions have $29M invested in ProShares Ultra NASDAQ Biotechnology in 2017 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 8 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
2.16% more ownership
Funds ownership: 4.44% → 6.6% (+2.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
33% less call options, than puts
Call options by funds: $9.71M | Put options by funds: $14.5M
Holders
40
Holding in Top 10
1
Calls
$9.71M
Puts
$14.5M
Top Buyers
| 1 | +$3.11M | |
| 2 | +$2.89M | |
| 3 | +$2.69M | |
| 4 |
PCA
Private Capital Advisors
Darien,
Connecticut
|
+$1.65M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$802K |
Top Sellers
| 1 | -$1.77M | |
| 2 | -$382K | |
| 3 | -$251K | |
| 4 |
LPL Financial
San Diego,
California
|
-$217K |
| 5 |
Koshinski Asset Management
Decatur,
Illinois
|
-$109K |